InVivoMAb Anti-Human RAGE/AGER Antibody (11E6#)

Description: InVivoMAb Anti-Human RAGE/AGER Antibody (11E6#) [11E6#] (RA14247) is a mouse monoclonal antibody detecting Advanced glycosylation end product-specific receptor in ELISA, FuncS. Suitable for Human.
Host species: Mouse
Isotype: IgG2a, kappa
Species reactivity: Human
Form: Liquid
Storage buffer: 0.01M PBS, pH 7.4.
Concentration: 1 mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: ELISA, FuncS
Target: Advanced glycosylation end product-specific receptor, Receptor for advanced glycosylation end products, AGER, RAGE
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: Please contact with the lab for this information.
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Advanced glycosylation end product-specific receptor (RAGE/AGER) is a ~42 kDa protein. Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, histones, phospholipids and glycosaminoglycans. Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. These ligands accumulate at inflammatory sites during the pathogenesis of various diseases including diabetes, vascular complications, neurodegenerative disorders and cancers, and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction of inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key pro-inflammatory mediators.
References:
1. Shang, D. et al. (2016) Scientific reports 6, 32180. PMID: 27572515
2. Evankovich, J. et al. (2017) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 31, 3894-3903. PMID: 2851515
3. Wang, G. et al. (2021) Cell death discovery 7, 337. PMID: 34743181
4. Yang, Y. et al. (2022) Communications biology 5, 824. PMID: 35974093
5. Sirois, CM. et al. (2013) The Journal of experimental medicine 210, 2447-63. PMID: 2408195
6. Xue, J. et al. (2011) Structure (London, England : 1993) 19, 722-32. PMID: 21565706
7. Sakaguchi, M. et al. (2011) PloS one 6, e23132. PMID: 21829704
8. Yan, Z. et al. (2021) Nature communications 12, 308. PMID: 33436632
9. Moroz, OV. et al. (2009) BMC biochemistry 10, 11. PMID: 19386136
10. Fang, F. et al. (2010) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24, 1043-55. PMID: 19906677
Note: For research use only. Not suitable for clinical or therapeutic use.